PATENT CLAIM ANALYSIS

Application Number: 16063170
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "210180"]

Abstract:
Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.

Claim (Index 76):
The method of any one of  claims 1 - 74  wherein the combination is concurrent administration of a first pharmaceutical composition comprising the therapeutically effective amount of the first agent and a second pharmaceutical composition comprising the therapeutically effective amount of the second agent.

Metadata:
- Claim Count in Document: 131.0
- Percentile: 94.0
- Lexical Diversity: 1.63158
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11581865', '15350801', '15683630', '13893141', '13461098']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7454903695259972
- 35 USC 102 Novelty (BERT): 0.5383260997394929
- Combined Prediction Score: 0.7247739425473467
- Mean Citation Score: 309.54825199999993
- Max Citation Score: 333.0288
- Similarity Product: 171.97271086263655

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test